The landscape of university based pre-clinical research is evolving rapidly. One of the most decisive and unidirectional shifts is toward a climate increased accountability, reproducibility, and the promotion of the downstream success of preclinical trials. The increased acceptance for the need to follow GLP standards represents a growing unwillingness of our industry to tolerate the traditionally low rates of translation of preclinical research to successful phase one clinical trials.
Here at the Duke PTRU we are committed to being early adopters of these increasingly strict standards of research excellence. We plan to meet and exceed the standards set forth by the GLP no matter how high they climb. As such the PTRU is committed to being fully GLP compliant now and in the future.